antisense gen2 reduction drugs!!

What will ATL1103 be worth to shareholders?

I don’t know if many of you know but when ISIS licensed Mipomersen to Genzyme it was done through auction style reverse bidding.

They got $175 million cash and 5 million Genzyme shares (worth $150 million) as an upfront payment... plus over 1billion in milestone payments to come.

ATL1103 is for a far, far more lucrative market than Mipomersen was... and is the same gen2 liver targeting antisense.

Now that antisense Gen2 liver reduction drugs hold commercial validation, NO tie-in partner takes on the same amount of risk that Genzyme did.

So what will ANP get as an upfront payment for ATL1103?

Going by what ISIS got from Genzyme, Iill be conservative and say $750 million as upfront payment and 2 billion in royalties over the next 10 year...

AND all this is happening before the New Year!

The directors are right when they say it will be a very Merry Christmas for ANP shareholders!



Good Luck!